Table 3.
Baseline characteristics and survival outcomes of SEER validation cohort, 2004-2014.
| Characteristic | D1CT | D1CRT | D2CT | D2CRT | P1 | P1 | P1 |
|---|---|---|---|---|---|---|---|
| (n=457) | (n=929) | (n=844) | (n=1,338) | D1CT vs. D2CRT | D1CRT vs. D2CRT | D2CT vs. D2CRT | |
| Age (years) | 0.039 | 0.22 | 0.23 | ||||
| <55 | 122 (26.7%) | 273 (29.4%) | 248 (29.4%) | 426 (31.8%) | |||
| ≥55 | 335 (73.3%) | 656 (70.6%) | 596 (70.6%) | 912 (68.2%) | |||
| Gender | 0.61 | 0.63 | 0.71 | ||||
| Male | 309 (67.6%) | 625 (67.3%) | 566 (67.1%) | 887 (66.3%) | |||
| Female | 148 (32.4%) | 304 (32.7%) | 278 (32.9%) | 451 (33.7%) | |||
| Race | < 0.001 | < 0.001 | < 0.001 | ||||
| White | 309 (67.6%) | 596 (64.2%) | 554 (65.6%) | 772 (57.7%) | |||
| Black | 59 (15.1%) | 158 (17.0%) | 113 (13.4%) | 190 (14.2%) | |||
| Other | 79 (17.3%) | 175 (18.8%) | 177 (21.0%) | 376 (28.1%) | |||
| Differentiation degree | 0.010 | 0.090 | 0.77 | ||||
| Poor differentiation | 304 (66.5%) | 648 (69.8%) | 621 (73.6%) | 977 (73.0%) | |||
| Well differentiation | 153 (33.5%) | 281 (30.2%) | 223 (26.4%) | 261 (27.0%) | |||
| Stage | < 0.001 | < 0.001 | < 0.001 | ||||
| ⅠB-ⅡB | 239 (52.3%) | 460 (49.5%) | 360 (42.7%) | 458 (34.2%) | |||
| Ⅲ | 218 (47.7%) | 469 (50.5%) | 484 (57.3%) | 880 (65.8%) | |||
| Survival outcomes | |||||||
| Cancer-specific survival (CSS) progression | |||||||
| Mean, months | 67.8 | 76.0 | 73.9 | 82.4 | < 0.001 | 0.012 | 0.002 |
| 3-year CSS | 49.6% | 54.5% | 56.6% | 59.9% | < 0.001 | 0.009 | 0.12 |
| 5-year CSS | 44.6% | 47.5% | 49.8% | 54.0% | < 0.001 | 0.002 | 0.052 |
| Overall survival (OS) | |||||||
| Mean, months | 60.6 | 67.5 | 67.8 | 76.5 | < 0.001 | 0.001 | 0.002 |
| 3-year OS | 45.2% | 49.7% | 53.3% | 56.9% | < 0.001 | 0.001 | 0.066 |
| 5-year OS | 39.6% | 40.7% | 46.0% | 49.8% | < 0.001 | < 0.001 | 0.058 |
Abbreviation: SEER: Surveillance, Epidemiology, and End Results program; D1CT: D1 dissection plus chemotherapy; D1CRT: D1 dissection plus chemoradiotherapy; D2CT: D2 dissection plus chemotherapy; D2CRT: D2 dissection plus chemoradiotherapy;
1P values are derived from Chi-square test or Fisher's exact test for categorical variables, and P values are derived from Log rank test for cancer-specific survival and Overall survival.